Generic Name and Formulations:
Racepinephrine 2.25%; inh soln.
Indications for ASTHMANEFRIN:
For temporary relief of shortness of breath, tightness of chest, and wheezing due to bronchial asthma.
Adults and Children:
For use in an atomizer (eg, EZ Breathe Atomizer). Add contents of one vial (0.5mL) to atomizer. <4yrs: not recommended. ≥4yrs: 1–3 inhalations not more than every 3 hours.
Within 14 days of MAOIs.
Heart disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Asthma requiring hospitalization. Discontinue and reevaluate if symptoms are not relieved within 20 minutes or worsen. Do not use if product is brown, pinkish or darker than slightly yellow in color, if it appears cloudy, or if it contains a precipitate. Pregnancy. Nursing mothers.
Caution with concomitant other asthma drugs.
Nervousness, tachycardia with excessive use.
Starter Kit—1 (10 vials + 1 EZ Breathe Atomizer); Refill vials—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline